English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduWith only a small percentage of Marylanders at high risk for lung cancer getting the recommended annual screening, the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) today launched a new statewide effort to increase annual screenings.
Tag: Astrazeneca
Technology Developed at Rutgers Sublicensed to Global Biopharmaceutical Company
Base editing technology invented at Rutgers, The State University of New Jersey, and exclusively licensed to Revvity, Inc. subsidiary Horizon Discovery, has been sub-licensed to biopharmaceutical company AstraZeneca to support its creation of cell therapies for the treatment of cancer and immune-mediated diseases.
NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects, in Collaboration with AstraZeneca
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer in collaboration with AstraZeneca.
The Society of Thoracic Surgeons and AstraZeneca Join Forces to Accelerate Lung Cancer and Disparities Research, Education
The Society of Thoracic Surgeons (STS) has entered into a partnership with biopharmaceutical company AstraZeneca in an effort to advance and improve lung cancer treatment and eliminate disparities in health care.
Data and safety review board reports how it monitored the COVID-19 vaccine trials
Evaluation of three vaccine candidates during the COVID-19 pandemic fell to 12 experts of the federally appointed COVID-19 Vaccine Data and Safety Monitoring Board. This team has now taken the unusual step of publishing details of their review process in The Journal of Infectious Diseases.